Heart. Published Online First: 11 October 2006. doi:10.1136/hrt.2006.102350
Original articles |
Antithrombotic therapy for peripheral arterial disease
1 Institute for Clinical Evaluative Siences, Canada
2 McMaster University, Canada
* To whom correspondence should be addressed. E-mail: danhackam{at}cogeco.ca.
Accepted 20 September 2006
Abstract
Patients with peripheral arterial disease bear a substantial risk for vascular events in the coronary, cerebral, and peripheral circulations. In addition, this disorder is associated with a systemic milieu characterized by ongoing platelet activation and heightened thrombogenesis; this milieu has been linked to subsequent cardiovascular events. These considerations suggest that some form of antithrombotic prophylaxis, consisting of either an antiplatelet or oral anticoagulant regimen, should be used in all patients with peripheral arterial disease. However, which agent to use has been a source of uncertainty, as evidence from randomized trials, meta-analyses and cost-benefit studies have often favored different approaches. This article synthesizes the available evidence and suggests that aspirin should remain the cornerstone of antithrombotic therapy for most patients with peripheral arterial disease.
Keywords: anticoagulants, antiplatelets, peripheral arterial disease, prevention, thrombosis
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
